Immunosuppressed oncology patients who develop pulmonary infiltrates during treatment have a mortality rate of the order of 55-90%. Early diagnosis and treatment is associated with increased survival. At present, diagnosis relies on invasive sampling of the respiratory tract using fibre-optic bronchoscopy. We have looked at a 30-month period, from June 1997 to December 1999, where 25 bronchoscopies were performed on patients from the Lymphoma and BMT units at The Royal Marsden Hospital for the further investigation of pulmonary infiltrates. Nine bronchoscopies (36%) yielded a positive result and seven (28%) led to a change in management. Analysis of the data showed that neither a positive result nor a change in management had any impact on overall survival. After reviewing the background literature on the investigation of pulmonary infiltrates in this group and discussion of the respective merits and limitations, we propose a management flowchart, with high-resolution computed tomography (HRCT) as the test arm in a future randomised trial of these patients. Bone Marrow Transplantation (2001) 27, 967-971. Keywords: oncology; HRCT; bronchoscopy The lung is a frequent site of infection in patients receiving treatment for malignancy. This occurs in up to 20% of cases and has a quoted mortality rate of 55-90%.
The lung is a frequent site of infection in patients receiving treatment for malignancy. This occurs in up to 20% of cases and has a quoted mortality rate of 55-90%. 1, 2 Although infection is the single most common cause of pulmonary infiltrates, a significant number are due to noninfective causes notably lung involvement with the primary malignancy, drug-related parenchymal disease, obliterative bronchiolitis, cryptogenic organising pneumonia (COP or BOOP), graft-versus-host disease and alveolar haemorrhage. The underlying pathogens are themselves dependent on the pattern of immunosuppression, as infections in patients with short bursts of neutropenia related to chemoCorrespondence: Dr M O'Brien, Lung Unit, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT UK Received 3 October 2000; accepted 13 February 2001 therapy differ from those patients at 60-90 days following bone marrow transplant. 3 Rapid diagnosis and treatment of pulmonary complications in the immunosuppressed oncology patient is associated with improved survival. 4 Diagnosis using bronchoscopy with bronchoalveolar lavage (BAL) is at present the routine procedure for the investigation of such patients. Earlier studies have shown that bronchoscopy and BAL is safe, has a high diagnostic yield of 50-80% for infections and, when associated with a positive management change, reduces overall mortality in the immunosuppressed oncology patient. [5] [6] [7] However, a study in 1997 from Johns Hopkins Bone Marrow Transplant (BMT) Unit has challenged the use of bronchoscopy. This group showed a diagnostic rate of only 31% and a change in management rate of 24% from a total of 68 procedures in 52 patients over a 2-year period. They had a high bronchoscopy complication rate of 15% (five acute respiratory failures, three pneumothoraces, one nose bleed and one death) with no overall associated survival benefit. The group's response was to re-evaluate the further routine use of bronchoscopy in their unit. 8 We have therefore looked at our own experience with bronchoscopy in patients from the Lymphoma and BMT Units at the Royal Marsden Hospital over a 30-month period and then gone on to review the literature. From this we have produced a possible algorithm for the future management of these patients based on the available evidence.
Materials and methods
The Lymphoma Unit sees approximately 200 new referrals per year with the BMT Unit performing approximately 75 marrow transplants (35 allogeneic and 40 autologous) over this same period. From a total number of just over 700 patients between June 1997 and December 1999, 25 needed further investigation with bronchoscopy and BAL because of either a CXR showing progressive pulmonary infiltrates or rapidly deteriorating clinical state. Fourteen of them were leukaemia patients (11 AML, one CLL, one MDS and one hairy cell) and 11 were lymphoma patients (eight NHL, two HL and one Burkitt's). Of those with leukaemia nine had received marrow transplants (six autografts, two allografts and one MUD) and five of the lymphoma patients had been treated with high-dose chemotherapy (one had an allograft).
Eighty-four percent were male with an overall median age of 48 (range 32-76). Six were mechanically ventilated at the time of the BAL. Seven patients had a platelet count Ͻ50 and six had a total white cell count Ͻ1.0 at the time of bronchoscopy. The median time lag from the first development of pulmonary infiltrates to bronchoscopy being performed was 7 days (range 0-35). Of the total, 14 bronchoscopies were performed by a SpR/Research Fellow and 11 by a Consultant Physician. There were no procedurerelated complications.
Results
Nine BALs yielded a positive result and seven of the nine led to a change in management. The pathogens isolated were two Aspergillus, two Parainfluenzae, two Streptococci, a Legionella (serotype 4/8/10/16 complex), a vancomycin-resistant Enterococcus and an isolate of Candida.
The overall median survival of all patients was 68 days (range 2-888). At the time of data analysis 14 of the 25 patients had died (56%).
Of the total number of patients, six had HRCTs performed. Of these, only the five most recent had the HRCT performed before bronchoscopy. Two of these five showed appearances characteristic of invasive aspergillosis. All five went on to bronchoscopy to exclude other co-existant pathogens, with all but one (VRE -no management change) yielding no positive microbiological isolates. Both the patients with CT evidence of aspergillosis, but with negative BAL, responded to antifungal treatment.
We compared survival, from the bronchoscopy date, of patients with and without a positive BAL result, along with the survival of those who had a management change due to the result. We used a log rank survival curve, with an event defined as patient death, censoring for those patients still alive at the end of the study period, by using their last date of follow-up as their event date. This was represented on the survival curves as a cross -the point where these patients' data was removed from the survival curve.
Our results show that neither a positive result nor a change in management had any impact on overall survival (Tables 1 and 2 , Figures 1 and 2 ). In fact, there appears to be a trend toward a shorter overall survival in those patients with a positive BAL. 
Discussion
Bronchoscopy is at present still the traditional first investigation in immunosuppressed patients developing pulmonary infiltrates. It offers the advantages that both direct vision and selective sampling can be performed from the worst affected sub-segmental bronchus. The two main procedures carried out at bronchoscopy are either transbronchial biopsy (TBB) or BAL, or a combination of the two.
The overall UK mortality rate for bronchoscopy is of the order of 0.04%, with a complication rate of 0.12%. 9 With the inclusion of TBB these rates rise to 0.12% and 2.7%, respectively. However, when looking at the high-risk immunosuppressed oncology population the complication rate rises to between 5% and 15% 8, 10 with the much higher complication rates in those having TBB due mainly to bleeding.
Several studies have looked at the yield of bronchoscopy in the immunosuppressed oncology patient with either BAL, TBB or both. The result of six of these studies from 1984 to 1995 5, 7, [11] [12] [13] [14] are summarised in Table 3 . BAL is less invasive than TBB, is well tolerated and is essentially devoid of direct complications. BAL appears to have an equivalent diagnostic yield to TBB when the underlying diagnosis is infection as in PCP (90%) and Aspergillus (40-50%).
Von Eiff et al 4 showed that management was changed in 65% of immunosuppressed cancer patients on the basis of BAL results and this had a significant effect on survival. Those in whom BAL confirmed empirical treatment had the highest overall survival rate of 88%. Where empirical treatment was changed as a result of bronchoscopic isolates, the survival rate was lower at 59%. In those patients, where no positive isolate or other cause was found at bronchoscopy, the survival rate was lowest at 35%. 4 Although this is a small cohort of patients, our group is comparable to previous studies. Ten of our patients had bone marrow transplants, over a quarter had profound neutopenia and/or thrombocytopenia and 6/25 were mechanically ventilated at the time of bronchoscopy. The median time lag from the first development of pulmonary infiltrates High-resolution computed tomography (HRCT) is a noninvasive technique that may well be complementary to or better than BAL/TBB. HRCT has found particular application in those patients with a normal CXR but respiratory symptoms and fever. [15] [16] [17] [18] Here, HRCT is of particular use in patients after a BMT, having a negative predictive value of 97%. 11 Other work recommends that the use of HRCT with guided BAL is the most sensitive way to diagnose pneumonia in the immunocompromised patient. 18, 19 The imaging appearances on HRCT of PCP, Kaposi's sarcoma and angioinvasive fungal infections has been well characterised in patients with HIV. [20] [21] [22] In the oncology setting, HRCT can show characteristic findings within 30 days of bone marrow transplantation (BMT) that are strongly suggestive of the diagnosis of angioinvasive aspergillosis. 19 This infection results in scattered foci of parenchymal inflammation, infarction and necrosis. CT shows a 'halo' of opacity surrounding focally dense parenchymal nodules. 19, 22 This halo is lower in attentuation than the nodule itself and has been termed the 'halo-sign', representing a rim of coagulation necrosis surrounding a central fungal nodule. 22, 23 CMV appearances on HRCT are of multiple small nodules with associated areas of ground glass shadowing. 24 Groups are now beginning to compare BAL with HRCT in the diagnosis of pulmonary fungal infections. In 1995 a different study by Von Eiff et al 7 reported a total of 56 patients with proven fungal pneumonia that had been investigated using both modalities. Overall, the sensitivity of BAL for Aspergillus fumigatus was 48%, with a specificity of 100%. HRCT was performed on 31 patients and was helpful towards the diagnosis in 26 episodes. In total, sensitivity of HRCT in diagnosing fungal pneumonia was 84%. These results are summarised in Table 4 . This group recommended the use of early HRCT, with not only empirical antibiotic treatment but also antifungal treatment. They suggested that BAL should be used to diagnose only atypical or mixed infections, or when infiltrates were not responding to treatment, and that TBB should be used where a noninfectious cause was being considered.
The early use of HRCT would diagnose a proportion of patients with aspergillosis or PCP and therefore could prevent the need for any invasive investigations. We have therefore formulated a flowchart using early HRCT to guide the further investigation of this patient group. Looking again at Table 3 , of the four trials with fully evaluable data, there were a total of 373 patients. If these patients had been managed using early HRCT, this could potentially have picked up the characteristic appearances of aspergillosis and PCP in 118 (32%) of the cases. This may have allowed these patients to have had a far less invasive investigation such as BAL alone as opposed to BAL and TBB. In our group, four of the patients may have had invasive aspergillosis diagnosed by HRCT (16%).
Other groups have used HRCT in neutropenic patients with continuing fever and normal CXR to detect pneumonia. However, all these patients with pneumonia would then go on to have a BAL. 11 Thus HRCT has not been previously used in this setting to stratify those patients in whom a BAL and/or a TBB should be performed, as we discuss below.
In conclusion, the studies discussed show an emerging consensus regarding both the use of FOB and the possible benefits of HRCT in oncology patients with pulmonary infiltrates.
It can be seen that BAL is applicable for the diagnosis of infective aetiologies particularly PCP, although both fungal and CMV infections are more problematic due to the low sensitivity. If there is a suspicion that the infiltrates may be non-infective in origin then the literature reviewed would support the addition of TBB to lavage. As discussed, the performance of TBB is associated with a substantial complication rate.
The early use of HRCT has been shown to be particularly sensitive at diagnosing invasive aspergillosis and is superior to BAL. HRCT can also be potentially used for the diagnosis of PCP and CMV.
With the evidence examined, along with our own data, we propose a new flowchart for the management of the oncology patient with new pulmonary infiltrates with HRCT having a central role (Figure 3) . Such an approach could be prospectively piloted and could then form the basis of a randomised clinical trial.
